JP2016522211A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522211A5 JP2016522211A5 JP2016516825A JP2016516825A JP2016522211A5 JP 2016522211 A5 JP2016522211 A5 JP 2016522211A5 JP 2016516825 A JP2016516825 A JP 2016516825A JP 2016516825 A JP2016516825 A JP 2016516825A JP 2016522211 A5 JP2016522211 A5 JP 2016522211A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pcsk9
- antibody
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 70
- 125000003275 alpha amino acid group Chemical group 0.000 claims 22
- 229940122392 PCSK9 inhibitor Drugs 0.000 claims 21
- 239000000427 antigen Substances 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 239000012634 fragment Substances 0.000 claims 20
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 14
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 14
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 102200057382 rs137852912 Human genes 0.000 claims 5
- 102200057375 rs28942111 Human genes 0.000 claims 5
- 102200057373 rs28942112 Human genes 0.000 claims 5
- 102200057387 rs370507566 Human genes 0.000 claims 5
- 102200057374 rs970575319 Human genes 0.000 claims 5
- 150000002632 lipids Chemical class 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 3
- 102200046719 rs104893870 Human genes 0.000 claims 3
- 102220244629 rs1278890129 Human genes 0.000 claims 3
- 102200054583 rs147675550 Human genes 0.000 claims 3
- 102220244637 rs185392267 Human genes 0.000 claims 3
- 102220285961 rs186669805 Human genes 0.000 claims 3
- 102200022418 rs56161402 Human genes 0.000 claims 3
- 102220132709 rs564427867 Human genes 0.000 claims 3
- 102220244634 rs569379713 Human genes 0.000 claims 3
- 102220197687 rs764603059 Human genes 0.000 claims 3
- 102220211581 rs778849441 Human genes 0.000 claims 3
- 102220095994 rs876660606 Human genes 0.000 claims 3
- 102200021819 rs981454067 Human genes 0.000 claims 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 108010028554 LDL Cholesterol Proteins 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 101150094724 PCSK9 gene Proteins 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 239000003613 bile acid Substances 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims 2
- 229960000815 ezetimibe Drugs 0.000 claims 2
- 229940125753 fibrate Drugs 0.000 claims 2
- -1 fibrate Substances 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 230000007935 neutral effect Effects 0.000 claims 2
- 235000001968 nicotinic acid Nutrition 0.000 claims 2
- 229960003512 nicotinic acid Drugs 0.000 claims 2
- 239000011664 nicotinic acid Substances 0.000 claims 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 2
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 2
- 239000006014 omega-3 oil Substances 0.000 claims 2
- 229920005989 resin Polymers 0.000 claims 2
- 239000011347 resin Substances 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 238000011285 therapeutic regimen Methods 0.000 claims 2
- 229940127355 PCSK9 Inhibitors Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361828730P | 2013-05-30 | 2013-05-30 | |
| US61/828,730 | 2013-05-30 | ||
| US201361889553P | 2013-10-11 | 2013-10-11 | |
| US61/889,553 | 2013-10-11 | ||
| US201361901212P | 2013-11-07 | 2013-11-07 | |
| US61/901,212 | 2013-11-07 | ||
| PCT/US2014/040050 WO2014194111A1 (en) | 2013-05-30 | 2014-05-29 | Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016522211A JP2016522211A (ja) | 2016-07-28 |
| JP2016522211A5 true JP2016522211A5 (OSRAM) | 2017-06-22 |
| JP6423868B2 JP6423868B2 (ja) | 2018-11-14 |
Family
ID=51205567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016516825A Active JP6423868B2 (ja) | 2013-05-30 | 2014-05-29 | Ｐｃｓｋ９機能獲得型変異に関連する常染色体優性高コレステロール血症を処置する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20140356370A1 (OSRAM) |
| EP (1) | EP3004172B1 (OSRAM) |
| JP (1) | JP6423868B2 (OSRAM) |
| KR (1) | KR20160013046A (OSRAM) |
| CN (2) | CN113144195A (OSRAM) |
| AU (1) | AU2014274077B2 (OSRAM) |
| CA (1) | CA2912101A1 (OSRAM) |
| EA (1) | EA201592304A1 (OSRAM) |
| IL (1) | IL242251B (OSRAM) |
| TW (1) | TWI682780B (OSRAM) |
| WO (1) | WO2014194111A1 (OSRAM) |
| ZA (1) | ZA201507798B (OSRAM) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| CN110711248A (zh) | 2011-01-28 | 2020-01-21 | 赛诺菲生物技术公司 | 包含针对pcsk9的人抗体的药物组合物 |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| ES2992345T3 (es) | 2011-09-16 | 2024-12-11 | Regeneron Pharma | Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9) |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| AU2014274844B2 (en) | 2013-06-07 | 2019-11-28 | Regeneron Pharmaceuticals, Inc. | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
| CA2926942A1 (en) * | 2013-10-11 | 2015-04-16 | Sanofi Biotechnology | Use of a pcsk9 inhibitor to treat hyperlipidemia |
| EP3068803B1 (en) | 2013-11-12 | 2021-01-20 | Sanofi Biotechnology | Dosing regimens for use with pcsk9 inhibitors |
| US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
| US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
| US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
| RU2735521C2 (ru) | 2014-07-16 | 2020-11-03 | Санофи Байотекнолоджи | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) |
| TW201628649A (zh) | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | 減少醫藥調配物中微可見顆粒之方法 |
| WO2016100615A2 (en) * | 2014-12-18 | 2016-06-23 | The University Of Chicago | Methods and composition for neutralization of influenza |
| US10772956B2 (en) | 2015-08-18 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab |
| WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| US11020686B2 (en) | 2016-08-16 | 2021-06-01 | Regeneron Pharmaceuticals, Inc. | Methods for quantitating individual antibodies from a mixture |
| BR112019006689A2 (pt) | 2016-10-25 | 2019-06-25 | Regeneron Pharma | métodos e sistemas para análise de dados de cromatografia |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| EP3609532A1 (en) | 2017-04-13 | 2020-02-19 | Cadila Healthcare Limited | Novel peptide based pcsk9 vaccine |
| CN110431153B (zh) * | 2017-06-30 | 2023-09-19 | 苏州盛迪亚生物医药有限公司 | 一种pcsk-9抗体药物组合物及其用途 |
| US12042538B2 (en) | 2017-09-19 | 2024-07-23 | Regeneron Pharmaceuticals, Inc. | Methods of reducing particle formation and compositions formed thereby |
| WO2019118187A1 (en) | 2017-12-13 | 2019-06-20 | Regeneron Pharmaceuticals, Inc. | Devices and systems for chromatography column bed support management and related methods |
| TWI853823B (zh) | 2018-07-02 | 2024-09-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
| EP4470609A3 (en) | 2019-01-18 | 2025-03-12 | Astrazeneca AB | Pcsk9 inhibitors and methods of use thereof |
| IL323016A (en) * | 2019-11-18 | 2025-10-01 | Ad Pharmaceuticals Co Ltd | Anti-pcsk9 antibody and its use |
| CA3161347A1 (en) | 2019-12-10 | 2021-06-17 | Shazia ALI | Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia |
| MX2023001912A (es) | 2020-08-25 | 2023-07-10 | Regeneron Pharma | Tratamiento de la sepsis con moduladores de pcsk9 y ldlr. |
| CN116189765B (zh) * | 2023-02-23 | 2023-08-15 | 上海捷易生物科技有限公司 | 一种iPS细胞遗传学风险评估系统及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1471152A1 (en) * | 2003-04-25 | 2004-10-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mutations in the human PCSK9 gene associated to hypercholesterolemia |
| US8357371B2 (en) | 2008-12-15 | 2013-01-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to PCSK9 |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| AR079336A1 (es) * | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
| AR088782A1 (es) * | 2011-04-29 | 2014-07-10 | Sanofi Sa | Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes |
| AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| ES2992345T3 (es) * | 2011-09-16 | 2024-12-11 | Regeneron Pharma | Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9) |
-
2014
- 2014-05-28 TW TW103118526A patent/TWI682780B/zh not_active IP Right Cessation
- 2014-05-29 CA CA2912101A patent/CA2912101A1/en not_active Abandoned
- 2014-05-29 AU AU2014274077A patent/AU2014274077B2/en not_active Ceased
- 2014-05-29 CN CN202110182897.4A patent/CN113144195A/zh active Pending
- 2014-05-29 KR KR1020157033966A patent/KR20160013046A/ko not_active Ceased
- 2014-05-29 WO PCT/US2014/040050 patent/WO2014194111A1/en not_active Ceased
- 2014-05-29 JP JP2016516825A patent/JP6423868B2/ja active Active
- 2014-05-29 EP EP14739600.6A patent/EP3004172B1/en active Active
- 2014-05-29 US US14/290,462 patent/US20140356370A1/en not_active Abandoned
- 2014-05-29 CN CN201480031344.7A patent/CN105263963B/zh active Active
- 2014-05-29 EA EA201592304A patent/EA201592304A1/ru unknown
-
2015
- 2015-10-19 ZA ZA2015/07798A patent/ZA201507798B/en unknown
- 2015-10-25 IL IL242251A patent/IL242251B/en not_active IP Right Cessation
-
2019
- 2019-03-28 US US16/367,795 patent/US20190330371A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016522211A5 (OSRAM) | ||
| JP2016520616A5 (OSRAM) | ||
| JP2017506626A5 (OSRAM) | ||
| JP2016538277A5 (OSRAM) | ||
| Cicero et al. | on behalf of the Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert Panel (ILEP)(2020) Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis | |
| Sun et al. | Late-stage failures of monoclonal antibody drugs: a retrospective case study analysis | |
| Melchiorri et al. | Alzheimer’s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy? | |
| JP2017528427A5 (OSRAM) | ||
| JP2018523684A5 (OSRAM) | ||
| Bertrand et al. | Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis | |
| JP2016538248A5 (OSRAM) | ||
| Li et al. | Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study | |
| JP2022000443A5 (OSRAM) | ||
| JP2019531273A5 (OSRAM) | ||
| JP2015514110A5 (OSRAM) | ||
| JP2019514907A5 (OSRAM) | ||
| Ceylan et al. | Clozapine regulates microglia and is effective in chronic experimental autoimmune encephalomyelitis | |
| FI3416684T3 (fi) | Menetelmiä ateroskleroosin hoitamiseksi tai ehkäisemiseksi antamalla ANGPTL3:n inhibiittoria | |
| RU2017104800A (ru) | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) | |
| JP2019512472A5 (OSRAM) | ||
| JP2016515134A5 (OSRAM) | ||
| Katsiki et al. | High-density lipoprotein, vascular risk, cancer and infection: a case of quantity and quality? | |
| JP2017533191A5 (OSRAM) | ||
| Islam et al. | GPCR19 Regulates P2X7R-Mediated NLRP3 inflammasomal activation of microglia by Amyloid β in a mouse model of Alzheimer’s disease | |
| JP2017533220A5 (OSRAM) |